Overview
The neuroendocrine component of the pancreas comprises highly specialized and tightly regulated cells responsible for the synthesis and secretion of specific peptide hormones. These cells are situated together within discreet, encapsulated and highly vascularized clusters called the islets of Langerhans, which are distributed throughout the pancreatic parenchyma. Approximately 3 million islets are present in the adult pancreas. The peptide hormones produced by specific islet cells include gastrin (G cells), insulin (beta cells), glucagon (alpha cells), vasoactive intestinal peptide (VIP, parasympathetic nerve cells), somatostatin (delta cells), and pancreatic polypeptide (PP, gamma/F cells), all of which are secreted directly into the associated islet blood supply. Under normal circumstances, the synthesis and secretion of each pancreatic neuroendocrine hormone are tightly regulated by intricate feedback mechanisms, so as to maintain normal physiology. However, overproduction of these hormones, often the result of tumor development from corresponding pancreatic neuroendocrine cells, can result in acute, potentially life-threatening morbidity. In general, emergent/life-threatening sequelae of excessive pancreatic neuroendocrine hormone production are not specific to the underlying hypersecretory tumor. Acute management therefore rarely involves direct diagnosis/treatment of the associated tumor but rather focuses on stabilization of the acutely ill patient.
Gastrinoma
Unlike most other pancreatic islet cells, G cells are not primarily pancreatic under normal circumstances, localizing also to the stomach antrum and duodenum. G cells are parasympathetic (vagal) neuroendocrine cells that function primarily to stimulate release of hydrochloric acid (HCl) from parietal cells of the stomach during digestion, which they mediate via gastrin secretion. The synthesis and secretion of gastrin, a 6–71-amino acid peptide (depending on the extent of posttranslational cleavage), are tightly regulated under normal circumstances: G cells secrete gastrin in response to vagal stimulation, stomach distention, increased blood calcium levels, and the presence of amino acids in the stomach. Gastrin secretion is normally inhibited by increasing stomach acidity, as well as by the regulatory hormones somatostatin, gastroinhibitory peptide, VIP, calcitonin, glucagon, and secretin.
Hypergastrinemia may result from inappropriate stimulation/loss of inhibition of otherwise normal G cells or, less commonly, from neoplastic G cell proliferation (gastrinoma). Approximately 25% of gastrinomas will develop from pancreatic G cells, with the incidence of pancreatic gastrinoma ranging between 0.1 and 0.4 per million individuals per year. Nonpancreatic gastrinomas may arise from the duodenum, stomach, liver, bile ducts, ovary, heart, or lung and the majority of gastrinomas are sporadic (approximately 80%), with most nonsporadic disease being associated with multiple endocrine neoplasia type 1 (MEN1). Gastrinomas develop disproportionately in men and diagnosis is most common between the ages of 20 and 50 years.
The clinical manifestations of gastrinoma are collectively known as Zollinger–Ellison syndrome (ZES) and are the result of hypergastrinemia. Among the etiologies potentially responsible for gastrin hypersecretion, gastrinoma and pernicious anemia produce the highest blood gastrin levels and, correspondingly, the most potentially severe associated symptoms. In general, these are related to peptic ulcer disease (which develops in over 90% of ZES cases), and/or malabsorption, and include abdominal/esophageal/thoracic pain (75% prevalence), diarrhea (73% prevalence), and nausea. Potential associated signs include gastrointestinal (GI) hemorrhage (25% prevalence), weight loss/malnourishment (17% prevalence), steatorrhea, GI obstruction, GI perforation, and anorexia/food intolerance.
ACUTE/EMERGENT DISEASE: PRESENTATION, MANAGEMENT, AND OUTCOMES
In most cases, development of gastrinoma-related signs/symptoms is gradual, characterized by increasingly symptomatic and medically refractory peptic ulcer disease. Gastrinoma is rarely diagnosed in the acute setting and emergent manifestations are generally the result of unrecognized/neglected progressive disease. These include life-threatening GI hemorrhage, GI perforation, and GI obstruction ( Table 16.1 ). It is important to note that management of these life-threatening disease manifestations is not specific to gastrinoma, but rather focuses on emergent stabilization of the acutely ill patient through resuscitative, supportive, and often surgical/procedural techniques. Such management usually occurs in the setting of an emergency department and always involves intravenous (IV) fluid resuscitation, basic biochemical (blood) testing, and diagnostic imaging, most commonly computed tomography (CT) scanning. The underlying diagnosis of gastrinoma, if not already known, is usually established and addressed well after urgent management is completed.
Emergent Manifestations | Critical Positive Diagnostic Features | Emergent Management: General Principles |
---|---|---|
| Vital signs: Shock PE/symptoms: Cognitive impairment related to severe volume depletion Biochemistry: Anemia Imaging: Upper GI bleeding, bleeding ulcer (EGD) |
|
| Vital signs: Developing/frank shock PE/symptoms: Epigastric pain, peritonitis, nausea Biochemistry: Leukocytosis Imaging: Intraabdominal free air, intraabdominal free fluid/fluid collection, oral contrast extravasation |
|
| Vital signs: Tachycardia, hypotension PE/symptoms: Intractable vomiting Biochemistry: Hypochlorremic, hypokalemic metabolic alkalosis Imaging: Gastric distention, restriction/failure of oral contrast progression at gastric outlet, bowel edema at gastric outlet |
|
Hemorrhage
GI hemorrhage, in this case from duodenal and/or gastric ulceration, is the most common emergent complication of peptic ulcer disease, accounting for 73% of cases. Acute presentation is characterized by signs/symptoms of significant blood loss/hemorrhagic shock. Biochemical testing reveals marked anemia and, potentially, thrombocytopenia. If associated end organ ischemic time is short, hypokalemic, hypochloremic alkalosis may be incidentally noted. This finding is suggestive of underlying hypergastrinemia and may help guide resuscitation strategy.
The management of shock is not unique to hypergastrinemia-mediated GI hemorrhage. All patients presenting in shock should be treated emergently using a basic resuscitative algorithm designed to abrogate progressive life-threatening multiorgan failure. Such algorithms have been thoroughly described in the critical care/trauma literature and include airway stabilization, ventilatory support, resuscitation, and transfusion, in the context of frequent/real time vital sign monitoring. Following successful resuscitative treatment, the underlying source(s) of bleeding must be identified. This requires diagnostic imaging, which may include CT arteriography, upper and lower endoscopy, catheter angiography and, potentially, tagged red cell scintigraphy and/or capsule endoscopy. For bleeding peptic ulcer disease, these imaging techniques, when positive, will reveal evidence of upper GI hemorrhage. In addition, CT scanning may identify one or more incidental abdominal soft tissue masses (gastrinomas) when ZES is present.
Endoscopy is always indicated when upper GI bleeding is suspected or is identified by nonendoscopic imaging. Associated sensitivity and specificity for bleeding ulcer identification exceed those of all other imaging modalities, approaching 98% and 100%, respectively. In addition, endoscopic intervention for active ulcer hemorrhage is generally employed simultaneously, including thermal coagulation, mechanical clipping, hemostatic spray/powder application, and/or epinephrine injection, thus making upper endoscopy both diagnostic and therapeutic. ZES is most commonly characterized by a solitary ulcer, usually less than 1 cm in diameter, localizing to the first portion of the duodenum (75% of cases). Nonetheless, a thorough upper endoscopic assessment is required, as multiple ulcers may be present and may localize to other portions of the upper GI tract, including the stomach, other domains of the duodenum, and/or the proximal jejunum.
Following emergent resuscitation, endoscopic intervention, as above, is the first-line treatment for bleeding peptic ulcers, achieving hemorrhage control in over 90% of cases. In the acute setting, ulcer discovery in general should also prompt IV treatment with a proton pump inhibitor and, if at all possible, any baseline anticoagulation should be reversed. Should endoscopic management fail to control ulcer bleeding, either during initial assessment or in the context of recurrence, surgical or endovascular approaches are indicated. These second-line options are generally considered equally effective, relative to one another. Catheter angiography with transarterial embolization is less invasive than surgery and success rates for initial bleeding control range between 52% and 98%. Surgical interventions include laparotomy, with enterectomy to oversew the ulcer and tamponade associated bleeding vessel(s), or ulcer resection with appropriate GI tract reconstruction, if the patient is stable. In each case, vagotomy and pyloroplasty should also be performed.
Perforation
GI perforation is a second life-threating manifestation of ZES ( Table 16.1 ). Like GI hemorrhage, perforation in this context is the result of advanced ulcer disease. These ulcers eventually erode through the full thickness of the stomach/bowel wall, ultimately allowing spillage of GI contents (including GI flora) into the peritoneal space. As such, acute presentation is the result of peritoneal irritation and, potentially, septic shock. Patients most often complain of sudden onset severe abdominal pain, with physical examination findings generally consistent with peritonitis, including rebound pain, focal epigastric tenderness, and guarding. Biochemical testing may reveal leukocytosis.
Immediate management focuses on resuscitation, especially if hemodynamic instability is present. Subsequent diagnostic imaging will reveal evidence of GI perforation. Upright abdominal plain film radiography may show subdiaphragmatic free air. More commonly, abdominal CT scanning is the initial diagnostic imaging performed, revealing free air and extraluminal fluid in the vicinity of the perforation. If oral contrast is used, this may be seen extravasating into the adjacent peritoneal space. Evidence of gastric/duodenal GI perforation requires prompt broad-spectrum IV antibiotic and proton pump inhibitor administration, as well as ongoing fluid resuscitation. In general, emergent surgery to address the perforation and remove the associated peritoneal soilage is then indicated, although nonoperative management, with or without percutaneous drainage, is an option for elderly patients having small, sealed perforations and who are poor surgical candidates.
Operative management most commonly involves laparotomy, although laparoscopic approaches have been described. Surgical options for perforated gastric ulcers include total gastrectomy (if underlying gastric malignancy cannot be excluded and the patient is stable, without significant peritoneal soilage), as well as gastric wedge resection or omental (Graham) patch repair, with vagotomy and pyloroplasty in both cases. Perforated duodenal ulcers may be managed with patching, especially in hemodynamically unstable patients, or by pyloroplasty (with perforation incorporation) and vagotomy. More complex procedures/resections are generally not required but may be necessary if a large perforation is present in a hemodynamically stable patient.
Gastric Outlet Obstruction
Inflammation and edema associated with progressive peptic ulcer disease involving the distal stomach and/or duodenum may cause gastric outlet obstruction ( Table 16.1 ). In the emergent setting, presenting signs and symptoms include intractable nonbilious vomiting, epigastric pain, abdominal distention, and dehydration. Biochemical testing may reveal hypochloremic, hypokalemic alkalosis, in the setting of prolonged vomiting and gastrinemia-mediated chronic HCl secretion. Diagnostic plain film imaging may demonstrate gastric distention (if the stomach has not been decompressed by nasogastric tube suctioning or excessive vomiting) and CT scanning with oral contrast will identify severe restriction/failure of contrast progression at the gastroduodenal junction, with bowel edema involving the gastric outlet.
Initial management focuses on fluid resuscitation, IV proton pump inhibitor administration, and basic biochemical testing, with correction of identified electrolyte abnormalities. Nasogastric tube placement with gastric decompression should be employed if abdominal distention is noted or when imaging reveals gastric outlet obstruction. Following resuscitation, upper endoscopy should be performed to delineate the cause of obstruction. For underlying peptic ulcer disease, an endoscopic balloon dilation is generally attempted. This requires advancement of the endoscope beyond the obstruction and is associated with a low rate of perforation, depending on the size of the balloon used. Recurrence rates in the context of ZES are unacceptably high, however, and successful initial balloon dilation is thus considered a temporizing measure in this context. Surgical management is therefore often required to definitively relieve the obstruction and treat the underlying ulcer disease. Options include open or laparoscopic distal gastrectomy/antrectomy with vagotomy, or bypass drainage with vagotomy.
Outcomes
Management outcomes for emergent manifestations of gastrinoma depend on specific presentation (upper GI hemorrhage, GI perforation, or gastric outlet obstruction), as well as on the extent of patient comorbidity. Mortality rates in the acute setting may be as high as 18% for peptic ulcer hemorrhage and 20% for peptic ulcer perforation, whereas these rates are exceedingly low in cases of peptic ulcer-related (benign) gastric outlet obstruction. Regardless, formal workup for gastrinoma is vitally important following successful acute management in these patients, as failure to establish this underlying diagnosis will increase the probability of recurrence in each case and may allow disease progression if malignant gastrinoma is present. Diagnosis is based on marked elevation in serum gastrin level (greater than 1000 pg/mL) or, in cases with less marked hypergastrinemia, on positive secretin stimulation testing.
Insulinoma
The insulin producing beta islet cells account for 60% to 85% of the endocrine pancreas. Insulin functions in glucose homeostasis by driving glucose uptake in skeletal muscle, liver, and adipose tissue, and by inhibiting both glycogenolysis and gluconeogenesis. Insulin synthesis and secretion are tightly regulated under normal circumstances, so as to maintain euglycemia. Excess insulin/hyperinsulinemia produces hypoglycemia, which results in end organ energy deprivation, the most severe manifestations of which are irreversible brain injury and death.
Insulinoma is the most common functional pancreatic neuroendocrine tumor, with an incidence of 4 cases per 1 million person years. Characteristically, these tumors secrete excess insulin, producing symptomatic hypoglycemia between meals in effected individuals. Approximately 90% of insulinomas are less than 2 cm in maximal diameter and tumors may localize at any site within the pancreas. Insulinomas are most commonly benign (90%) and are generally discreetly localized/noninvasive. Given the small nature of most insulinomas, symptoms related to associated mass/mechanical effects are rare.
ACUTE/EMERGENT DISEASE: PRESENTATION, MANAGEMENT, AND OUTCOMES
Emergent/life threatening manifestations of insulinoma are the result of severe hypoglycemia, which, if left untreated, can result in irreversible brain injury or death ( Table 16.2 ). A nondiabetic hypoglycemic patient presenting with symptoms of sympathoadrenal activation, such as tremors, sweating, and palpitations, should raise concern for a diagnosis of insulinoma. Regardless of underlying diagnosis, however, expeditious management of hypoglycemia is the most critical component of emergent care in these patients.